Anika Therapeutics Inc. (ANIK)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 23/100 (LOW), 88.3 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 3.38% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
- Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
- AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
- NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
- PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
- RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
- Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
- Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Anika Therapeutics Inc..
Full ANIK Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.